Medscape

The Medical and Surgical Management of Short Bowel Syndrome

In the absence of registry data, it is impossible to know the precise incidence and prevalence of short bowel syndrome in the United States. On the basis of European data, the incidence of total ...
Business Wire

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2024 Annual ...
Medscape

Teduglutide Reduces Parenteral Support Needs in Short Bowel

Teduglutide (Revestive, Nycomed/Takeda, in the European Union; Gattex, NPS Pharmaceuticals, in the United States) appears to reduce the need for parenteral support in patients with short bowel ...
Nature

Short Bowel Syndrome and Parenteral Nutrition

Short Bowel Syndrome (SBS) is a multifaceted condition arising from extensive surgical resection of the small intestine, which leads to impaired nutrient absorption and a heightened risk of ...
Healio

Teduglutide improves stool outcomes in children with short bowel syndrome over 96 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Stool frequency and consistency improved over 96 weeks ...
Business Insider

Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially ...

Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that the first short bowel syndrome with intestinal failure (SBS-IF) ...
Becker's Hospital Review

Short Bowel Syndrome Drug Receives FDA Drug Advisory Committee Recommendation

Gattex (teduglutide), a drug for the treatment of adult short bowel syndrome, has received a recommendation for approval from the FDA’s Gastrointestinal Drugs Advisory Committee, according to a news ...
USA Today

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones

This new IP supports crofelemer’s global exclusivity in rare pediatric intestinal failure coincident with published clinical data showing reductions in parenteral support requirements with crofelemer ...
clinicaladvisor.com

Apraglutide Gets Orphan Drug Designation for Short Bowel Syndrome

FDA orphan drug granted. The Company has already completed a Phase 1 trial of this synthetic glucagon-like peptide (GLP-2) analog. The Food and Drug Administration (FDA) has granted Orphan Drug ...